Molecular and clinical risk markers in colon cancer trials.
Although there is a great deal of information concerning the risk factors for colorectal cancer, progress has been slow in determining methods of chemoprevention. In part this is because colorectal cancer consists of a series of events over 10-15 years or more, which affects only 3-5% of the population. Risk markers for use in patient selection are needed to decrease the sample size needed. In addition, there is a need to identify intermediate endpoints of success to decrease the follow-up time. Clinical markers of risk are a history of colorectal adenomas and of inflammatory bowel disease. Molecular markers include a number of genetic markers and enzyme polymorphisms.
Hill
M J
MJ
European Cancer Prevention Organization, Lady Sobell Gastrointestinal Unit, Wexham Park Hospital, SL2 4HL, Slough, UK. teres.edit@home-office1.demon.co.uk
D000236:Adenoma / Q000209:etiology*; D011125:Adenomatous Polyposis Coli / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000235:genetics / Q000517:prevention & control*; D005260:Female; D005819:Genetic Markers / Q000502:physiology; D006801:Humans; D008297:Male; D009154:Mutation / Q000235:genetics; D011230:Precancerous Conditions / Q000150:complications; D012307:Risk Factors
D014408:Biomarkers, Tumor; D005819:Genetic Markers